Innate Immunity in COPD

Launched by UNIVERSITY OF EDINBURGH · Feb 14, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Innate Immunity in COPD," is studying how the immune system works in people with Chronic Obstructive Pulmonary Disease (COPD). COPD is a serious lung condition that makes it hard to breathe and is often caused by smoking. The researchers are particularly interested in understanding why certain immune cells in the lungs struggle to fight off bacteria, which can lead to more lung damage. By examining cells collected from the lungs and the blood of participants, they hope to learn more about how these cells use energy and how this affects their ability to respond to infections. The ultimate goal is to find new ways to treat and manage COPD.

To participate in this study, people must be between the ages of 18 and 77 and have been diagnosed with COPD, specifically at GOLD Stage 1, 2, or 3. Some healthy volunteers who do not have COPD can also join. Participants will undergo procedures like blood donation or bronchoscopy (a test where a small camera is placed in the lungs) to collect samples. It's important to note that individuals with certain health conditions, such as active cancer or severe kidney problems, cannot take part in the study. Overall, this trial aims to improve our understanding of COPD and help develop better treatment options for those affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• COPD patients:
• • COPD patients aged 18-77 years who are GOLD Stage 1 or 2 or 3; for patients undergoing bronchoscopy already for a clinical reason.
• • COPD patients aged 18-77 years old who are GOLD Stage 1,2 or 3 for patients who are donating blood only.
• • COPD patients aged 18-69 years who are GOLD Stage 1 or 2 for patients undergoing bronchoscopy for research purposes.
• • COPD- Defined by radiological investigation of chest either chest X-ray or High-resolution CT scan in previous 12 months
• • Ability to provide informed consent
• Healthy volunteers:
• • Any healthy volunteer aged 18-77 years
• • Ability to provide informed consent
• Exclusion Criteria:
• COPD patients:
• • Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure.
• • Individuals with a history of anaemia
• • Individuals who have donated \>250 ml of blood for any reason within the last 6 months
• • Individuals who are pregnant or breast feeding.
• • Current participation in any other clinical trial, except those directly relating to this cohort and study.
• • Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks
• • Individuals who have received a vaccine in the past 2 weeks
• • Inability to communicate in English or convey willingness to participate.
• * For bronchoscopy - Any significant lung condition that would contra-indicate bronchoscopy including:
• • active acute lung infection (with the exception of asymptomatic pulmonary colonisation) or malignancy, significant coexisting interstitial lung disease or additional pulmonary diagnosis in addition to COPD.
• Healthy volunteers:
• • Individuals known to have active malignancy, immunosuppression, diabetes mellitus, chronic kidney disease or hepatic failure
• • Individuals with anaemia on the screening full blood count (FBC)
• • Individuals who donated \>250 ml of blood for any reason within the last 6 months
• • Individuals who are pregnant or breast feeding
• • Current participation in any other clinical trial
• • Individuals who have had a febrile illness or other symptoms of acute infectious illness (respiratory, enteric or soft tissue) within the last 2 weeks.
• • Individuals who have received a vaccine in the past 2 weeks
• • Chronic or acute respiratory disease.
• • Any chronic medical condition or receipt of regular prescription medication other than the oral contraceptive pill.
• • Inability to communicate in English or convey willingness to participate
• • For bronchoscopy - Any active lung condition including any lung infection or asthma Any significant abnormality on CXR that would contraindicate bronchoscopy FEV1 \<65% predicted (BTS Guidelines, 2001)